On the way to the company, Jiang Bo received a call from Zhuang Miao.

Zhuang Miao was previously responsible for the procurement of bracelet factory equipment, and was later transferred by Hou Xu to Shanghai to preside over the investigation of Zhongrun Pharmaceutical Company.

In normal times, Jiang Bo basically never received a call from Zhuang Miao, but now that he is calling, it must be that there has been a new development in the situation of Zhongrun Pharmaceutical Company.

Thinking of this, Jiang Bo's heart was hot, and he hurriedly answered the phone and asked, "Is there something wrong?"

Zhuang Miao said: "Boss, the investigation of Zhongrun Pharmaceutical Company here in Shanghai has made a breakthrough, Mr. Hou said before that I would report it to you directly, and I didn't bother you, right?"

"Nope. Jiang Bo's eyes lit up slightly, and he asked, "To what extent, tell me?"

Zhuang Miao said: "After more than two months of secret investigation and evidence collection, we have basically dug out all the information that can be excavated, the amount of information is a bit large, I can't tell for a while on the phone, I plan to send the relevant information directly to your mailbox, what do you think?"

"No need. Jiang Bo's eyes flickered a few times and said, "I'll book a plane ticket and rush over, and after we arrive, let's focus on chatting." ”

"Okay, then I'll pick you up at the airport then. ”

After hanging up the phone, Jiang Bo booked a ticket to Shanghai online through his mobile phone, and then drove straight to the airport.

In fact, a long time ago, Jiang Bo wanted to go to Shanghai to see the geographical location of Zhongrun Pharmaceutical Company and the appearance of the company, but he has been delayed by various things.

Now Zhuang Miao called to say that a breakthrough had been made in the investigation of Zhongrun Pharmaceutical Company.

So it just so happened that with the help of this opportunity, Jiang Bo went to Shanghai for a trip.

……

Three and a half in the afternoon.

A medium-sized Boeing 737 passenger plane from China Eastern Airlines successfully landed at Phut International Airport.

Zhuang Miao came to pick him up, and after Jiang Bo met him, he went all the way out of the airport and took a car to the Lujiazui financial circle.

On the 18th floor of an office building, Jiang Bo met with three other company employees, two men and one woman, named Xiang Chengfei, Wen Jiajing and Liu Hao.

In order to facilitate the office, Zhuang Miao and the others came here to rent two offices after they came to Shanghai, which were used as temporary offices of Black Bone Technology Company.

Although the area is not large, it is enough for them to discuss work here.

In an office, Jiang Bo sat on a black leather chair, took a sip of Wen Jiajing's coffee, and looked at Zhuang Miao next to him.

Zhuang Miao hurriedly handed the documents that had been prepared long ago to Jiang Bo: "Boss, this is all the information, you can take a look." ”

Jiang Bo glanced at the document that was at least two fingers thick, and said in surprise, "Is it so much?"

As he spoke, he took it and looked at it for two minutes, and said helplessly: "Forget it, I'm afraid it's going to be tomorrow after reading this, so you should tell me it directly." ”

"Okay. Zhuang Miao nodded with a smile, and then said, "Our investigation of Zhongrun Pharmaceutical Company is mainly aimed at their corporate structure, financial status, and operating costs...... Conduct risk checks to see if they have significant financial risks and potential headwinds......"

Zhuang Miao had participated in acquisitions at other companies before joining Black Bone Technology, so he was familiar with this process.

The investigation of Zhongrun Pharmaceutical Company first investigated their historical evolution information, such as shareholder changes, equity transfers, registered capital changes, etc., as well as the company's organizational structure, such as the layout of management levels, directors, supervisors and senior executives.

The second is the company's business, mainly the business scale, business scope, corresponding business qualifications, overall operating data and other information of Zhongrun Pharmaceutical Company.

For example, whether there is illegal operation, whether the qualifications are complete, whether there is a record, whether the company information disclosed on the relevant national website is normal, etc.

Then there are the company's personnel, who mainly investigate the salary level, five insurances and one housing fund, and labor relations issues.

Then there is the analysis of the company's financial statements and financial position, which is the focus of this focus.

Generally speaking, it is to investigate the financial statement data of a period, including the financial statements, income statement, and cash flow statement of the period.

However, because Zhuang Miao and others were secretly investigating, this kind of financial investigation could not get detailed data at all.

Only when they are approached by the senior management of Zhongrun Pharmaceutical Company and express their intention to acquire or raise funds, and their bid is within the scope of the other party's negotiability, can they conduct an investigation and understand the specific situation.

Before that, they could only get an approximate valuation, and the task assigned by Hou Xu must be a complete financial due diligence, so they had to try their best to investigate.

In the end, it took more than a month for Zhuang Miao and others to figure out the specific situation.

Jiang Bo frowned halfway through hearing this: "You mean, the assets of Zhongrun Pharmaceutical Company are 1.23 billion, is there so much?"

Before, some news and information learned from the Internet made Jiang Bo think that the assets of Zhongrun Pharmaceutical Company were only a few hundred million, but now Zhuang Miao told him that it actually exceeded 1 billion, reaching 1.23 billion, which was different from what Jiang Bo expected.

Moreover, if this is the case, then I am afraid that he will not be able to complete the acquisition of Zhongrun Pharmaceutical Company in a short period of time.

That's not good news.

However, Zhuang Miao's words made Jiang Bo breathe a sigh of relief.

Zhuang Miao said: "Yes, the valuation of the assets of Zhongrun Pharmaceutical Company is the valuation we calculated after more than two months of strict investigation and evidence collection, and we have also checked with their internal personnel through some means, and the results are basically correct."

However, assets refer to total assets, not their net worth.

If they want to acquire Zhongrun Pharmaceutical Company, they will naturally not bear liabilities other than their net assets.

And the amount of their net worth is about 700 million, even if there is a disparity, but the range of ups and downs will not exceed 50 million. ”

Generally speaking, the acquisition of a company is more about acquiring its existing net assets, rather than its total assets, including net assets and liabilities.

The total assets of Zhongrun Pharmaceutical Company are about 1.23 billion, but the liabilities are 530 million, and the debt ratio is as high as 43%, which is not too high, but it is not low.

After calculation, the net assets are about 700 million, and the floating range of 50 million up and down is normal.

Zhuang Miao continued: "In terms of income, the current Zhongrun Pharmaceutical Company can be said to be unable to make ends meet.

Because of the casualty accident that occurred in the first half of the year, they suffered a lawsuit and paid a lot of compensation.

And the survival space of the drug market has been further suppressed by other competitors.

According to our survey, Zhongrun Pharmaceutical's revenue in the third quarter of this year was only 82 million, but the expenditure was as high as 136 million, showing a negative profit.

According to the internal information we have obtained, the available liquidity on the books of Zhongrun Pharmaceutical Company is less than 12 million......"